市場調查報告書

mRNA疫苗、治療藥的全球市場預測 (2019-2029年)

mRNA Vaccines and Therapeutics Market Forecast 2019-2029

出版商 Visiongain Ltd 商品編碼 886295
出版日期 內容資訊 英文 184 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
mRNA疫苗、治療藥的全球市場預測 (2019-2029年) mRNA Vaccines and Therapeutics Market Forecast 2019-2029
出版日期: 2019年05月07日內容資訊: 英文 184 Pages
簡介

2018年的mRNA疫苗、治療藥市場規模,估計為34億3,000萬美元。預測標準化癌症治療用mRNA疫苗的市場區隔2018年構成35.47%的佔有率,今後10年將以9.77%的年複合成長率 (CAGR) 擴大。

本報告提供全球mRNA疫苗、治療藥市場調查,市場概要,市場的各種影響因素及市場機會分析,各市場區隔、各地區/主要國家趨勢與市場規模的變化與預測,開發平台分析,主要企業簡介等資訊彙整。

第1章 調查概要

第2章 簡介

  • mRNA疫苗、治療藥的發展歷史
  • 慢性疾病、主要的感染疾病的發生率、盛行率
  • 使用了mRNA疫苗、治療藥的預防、治療

第3章 mRNA & 輸送技術的簡介

  • Ex vivo (離體) mRNA 加載
  • In vivo (體內) 載體 & mRNA
  • In vivo (體內) 載體 & mRNA

第4章 全球mRNA疫苗、治療藥:市場規模、預測

  • mRNA疫苗、治療藥市場概要
  • 全球mRNA疫苗、治療藥市場
  • 全球mRNA疫苗、治療藥市場:銷售預測
  • 市場佔有率的變化:各地區

第5章 mRNA疫苗、治療藥市場:促進因素、阻礙因素、趨勢分析

  • mRNA疫苗、治療藥市場:促進因素
  • mRNA疫苗、治療藥市場:阻礙因素
  • mRNA疫苗、治療藥市場:趨勢

第6章 mRNA疫苗、治療藥市場:各類型的市場規模、預測

  • 市場預測
  • mRNA疫苗、治療藥的市場佔有率:各類型

第7章 mRNA疫苗、治療藥市場:各作用機制的市場規模、預測

  • 市場預測
  • mRNA疫苗、治療藥的市場佔有率:各作用機制

第8章 mRNA疫苗、治療藥市場:各地區的市場規模、預測

  • 市場預測
  • 北美:市場佔有率、預測
  • 歐洲:市場佔有率、預測
  • 亞太地區:市場佔有率、預測
  • 其他 (RoW) :市場佔有率、預測

第9章 mRNA疫苗、治療藥市場:研發產品線分析

  • 有前途的開發平台分子分析
  • 標準化mRNA癌症疫苗
  • 治療用mRNA感染疾病疫苗
  • 個體化mRNA癌症疫苗
  • 染色體的複製RNA感染疾病疫苗
  • 預防mRNA感染疾病疫苗
  • 鳥胺酸氨甲醯基轉移酶缺乏症用mRNA蛋白質治療藥
  • 癌症、心血管疾病mRNA蛋白質治療藥
  • 囊狀纖維化症mRNA蛋白質治療藥
  • 其他遺傳基因疾病mRNA蛋白質治療藥
  • 治療用mRNA型遺傳基因編輯
  • mRNA抗體治療藥

第10章 mRNA疫苗、治療藥市場:主要企業

  • Moderna Therapeutics
  • Sangamo Therapeutics
  • Argos Therapeutics
  • CureVac
  • Translate Bio
  • BioNTech
  • In-Cell-Art
  • eTheRNA Immunotherapies
  • ethris GmbH
  • Tiba Biotech

第11章 結論

附錄

目錄
Product Code: PHA0418

The mRNA Vaccines and Therapeutics Market is estimated at $3.43 billion in 2018. The Standardized Therapeutic Cancer mRNA Vaccines segment held a share of 35.47% in 2018 and is projected to grow with a CAGR of 9.77% in next ten years.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 184-page report you will receive 130 charts- all unavailable elsewhere.

The 184-page report provides clear detailed insight into the mRNA Vaccines and Therapeutics Market. Discover the key drivers and challenges affecting the market.

Report Scope

Revenue and growth forecasts from 2019 to 2029 for the mRNA Vaccines and Therapeutics market

Revenue and growth forecasts from 2019 to 2029 for the mRNA Vaccines and Therapeutics market by type:

  • Standardized Therapeutic Cancer mRNA Vaccines
  • Individualized Therapeutic Cancer mRNA Vaccines
  • Therapeutic Infectious Disease mRNA Vaccines
  • mRNA Therapeutic for Other Diseases

Revenue and growth forecasts from 2019 to 2029 for the mRNA Vaccines and Therapeutics market by Mechanism of Action:

  • Bioengineered Vaccine
  • Gene Therapy (Gene Silencing/Suppression)
  • Gene Transcription (Protein Generation)
  • Cell Therapy
  • Monoclonal Antibody
  • Others

Revenue and growth forecasts from 2019 to 2029 for the leading regional and national markets:

North America: the revenues are further broken down into the US and Canada

Europe: the revenues are further broken down into the UK, Germany, France, Italy and Spain

Asia-Pacific: the revenues are further broken down into China, Japan and India

Rest of the World: the revenues are further broken down into Brazil, Mexico, Russia and South Africa

Discussion and profiles of the leading players in the mRNA Vaccines and Therapeutics market:

  • Argos Therapeutics, Inc.
  • BioNTech AG
  • CureVac AG
  • eTheRNA Immunotherapies
  • ethris GmbH
  • In-Cell-Art
  • Moderna Therapeutics
  • Sangamo Therapeutics, Inc.
  • Tiba Biotech
  • Translate Bio, Inc.

Discussion on mRNA & Delivery Technologies covering Arcelis Technology, Flow Electroporation Technology, Hybrid mRNA Technology, Lipid Nanoparticle (LNP) mRNA Technology, Nanotaxi Technology, RNArt & RNAntibody Technology, UNA & LUNAR Technologies, RNActive Technology, Self-Amplifying mRNA (SAM) Technology, TriMix Technology

Qualitative analysis of factors that drive and restrain the mRNA Vaccines and Therapeutics market. Trends analysis of the mRNA Vaccines and Therapeutics market.

mRNA Vaccines and Therapeutics R&D pipeline analysis

Key Questions Answered by this Report:

  • How is the mRNA vaccines and therapeutics market evolving?
  • What is driving and restraining the mRNA vaccines and therapeutics market?
  • What are the market shares of the leading segments of the mRNA vaccines and therapeutics market in 2018?
  • What will be the main driver of the overall market from 2019 to 2029?
  • How will the market shares of the leading national markets change by 2029 and which country will lead the market in 2029?
  • How will the industry evolve during the period between 2019 and 2029?
  • Who are the leading companies in this market?

Visiongain's study is intended for anyone requiring commercial analyses for the mRNA Vaccines and Therapeutics market. You find data, trends and predictions.

Buy our report today mRNA Vaccines and Therapeutics Market Forecast 2019-2029: Standardized Therapeutic Cancer mRNA Vaccines, Individualized Therapeutic Cancer mRNA Vaccines, Therapeutic Infectious Disease mRNA Vaccines, mRNA Therapeutic for Other Diseases, Bioengineered Vaccine, Gene Transcription, Monoclonal Antibody, Gene Therapy, Cell Therapy.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 Global mRNA Vaccines and Therapeutics Market Overview
  • 1.2 Global mRNA Vaccines and Therapeutics Market Segmentation
  • 1.3 Overview of Findings
  • 1.4 Structure of the Report
  • 1.5 Why You Should Read This Report
  • 1.6 How This Report Delivers
  • 1.7 Main Questions Answered by this Report
  • 1.8 Who is this Report for?
  • 1.9 Research and Analysis Methods
  • 1.10 Frequently Asked Questions (FAQ)
  • 1.11 Associated Reports
  • 1.12 About Visiongain

2. Introduction to mRNA Vaccines and Therapeutics

  • 2.1 History of mRNA Vaccines & Therapeutics Development
  • 2.2 Incidence and Prevalence of Chronic Diseases and Major Infectious Diseases
  • 2.3 Prevention and Treatment Using mRNA Vaccines & Therapeutics
    • 2.3.1 mRNA Modifications
    • 2.3.2 mRNA Efficiencies
    • 2.3.3 Adjuvant/Stimulant & Carrier Technologies for mRNA-based Vaccines
    • 2.3.4 Carriers for mRNA-based Protein & Antibody Therapeutics

3. Introduction of mRNA & Delivery Technologies

  • 3.1 Ex vivo mRNA Loading
    • 3.1.1 Arcelis Technology
    • 3.1.2 Flow Electroporation Technology
  • 3.2 In vivo Carrier & mRNA
    • 3.2.1 Hybrid mRNA Technology
    • 3.2.2 Lipid Nanoparticle (LNP) mRNA Technology
    • 3.2.3 Nanotaxi Technology
    • 3.2.4 RNArt & RNAntibody Technology
    • 3.2.5 UNA & LUNAR Technologies
  • 3.3 mRNA Vaccines & Stimulants / Adjuvants
    • 3.3.1 RNActive Technology
    • 3.3.2 Self-Amplifying mRNA (SAM) Technology
    • 3.3.3 TriMix Technology

4. Global mRNA Vaccines & Therapeutics: Market Size and Forecast 2019-2029

  • 4.1 mRNA Vaccines and Therapeutics Market Overview, 2018
  • 4.2 The World mRNA Vaccines and Therapeutics Market
  • 4.3 World mRNA Vaccines and Therapeutics Market: Sales Forecast 2019-2029
  • 4.4 Changing Market Shares by Region 2018-2029

5. mRNA Vaccines and Therapeutics Market: Drivers, Restraints, and Trends Analysis 2019-2029

  • 5.1 mRNA Vaccines and Therapeutics Market: Drivers 2019-2029
    • 5.1.1 Rising Adoption of Personalized Medicine for Effective Treatment
    • 5.1.2 Advantages Offered by mRNA-based Products
    • 5.1.3 Rising Funding by Pharmaceutical Companies and Government Organizations
  • 5.2 mRNA Vaccines and Therapeutics Market: Restraints 2019-2029
    • 5.2.1 Delivery of mRNA therapeutics and vaccines
    • 5.2.2 Stringent Government Regulations for mRNA-based Product Approvals
  • 5.3 mRNA Vaccines and Therapeutics Market: Trends 2019-2029
    • 5.3.1 Rising adoption of gene therapy-based products

6. mRNA Vaccines & Therapeutics by Type: Market Size and Forecast 2019-2029

  • 6.1 Market Forecast 2019-2029
  • 6.2 Market Share of mRNA Vaccines and Therapeutics by Type
    • 6.2.1 Standardized Therapeutic Cancer mRNA Vaccines: Market Forecast, 2019-2029
    • 6.2.2 Individualized Therapeutic Cancer mRNA Vaccines: Market Forecast, 2019-2029
    • 6.2.3 Therapeutic Infectious Disease mRNA Vaccines: Market Forecast, 2019-2029
    • 6.2.4 mRNA Therapeutic for Other Diseases: Market Forecast, 2019-2029

7. mRNA Vaccines & Therapeutics by Mechanism of Action: Market Size and Forecast 2019-2029

  • 7.1 Market Forecast 2019-2029
  • 7.2 Market Share of mRNA Vaccines and Therapeutics by Mechanism of Action
    • 7.2.1 Bioengineered Vaccine: Market Forecast, 2019-2029
    • 7.2.2 Gene Therapy (Gene Silencing/Suppression): Market Forecast, 2019-2029
    • 7.2.3 Gene Transcription (Protein Generation): Market Forecast, 2019-2029
    • 7.2.4 Cell Therapy: Market Forecast, 2019-2029
    • 7.2.5 Monoclonal Antibody: Market Forecast, 2019-2029
    • 7.2.6 Others: Market Forecast, 2019-2029

8. mRNA Vaccines & Therapeutics Regional Market: Market Size and Forecast 2019-2029

  • 8.1 Leading National Markets of mRNA Vaccines & Therapeutics 2019-2029
  • 8.2 North America mRNA Vaccines & Therapeutics: Market Size and Forecast 2019-2029
    • 8.2.1 The US mRNA Vaccines and Therapeutics: Market Forecast 2019-2029
    • 8.2.2 Canada mRNA Vaccines and Therapeutics: Market Forecast 2019-2029
  • 8.3 Europe mRNA Vaccines & Therapeutics: Market Size and Forecast 2018-2029
    • 8.3.1 Germany mRNA Vaccines and Therapeutics: Market Forecast 2019-2029
    • 8.3.2 UK mRNA Vaccines and Therapeutics Market: Forecast 2019-2029
    • 8.3.3 French mRNA Vaccines and Therapeutics Market: Forecast 2019-2029
    • 8.3.4 Italian mRNA Vaccines and Therapeutics: Market Forecast 2019-2029
    • 8.3.5 Spanish mRNA Vaccines and Therapeutics: Market Forecast 2019-2029
  • 8.4 Asia-Pacific mRNA Vaccines & Therapeutics Market Size and Forecast 2019-2029
    • 8.4.1 Japanese mRNA Vaccines and Therapeutics: Market Forecast 2019-2029
    • 8.4.2 Chinese mRNA Vaccines and Therapeutics: Market Forecast 2019-2029
    • 8.4.3 Indian mRNA Vaccines and Therapeutics: Market Forecast 2019-2029
  • 8.5 Row mRNA Vaccines & Therapeutics Market Size and Forecast 2018-2029
    • 8.5.1 Brazilian mRNA Vaccines and Therapeutics: Market Forecast 2019-2029
    • 8.5.2 Mexico mRNA Vaccines and Therapeutics: Market Forecast 2019-2029
    • 8.5.3 Russia mRNA Vaccines and Therapeutics: Market Forecast 2019-2029
    • 8.5.4 South Africa mRNA Vaccines and Therapeutics: Market Forecast 2019-2029

9. mRNA Vaccines & Therapeutics R&D Pipeline Analysis, 2018

  • 9.1 Promising Pipeline Molecules Analysis
  • 9.2 Standardized mRNA Cancer Vaccines
  • 9.3 Therapeutic mRNA Infectious Disease Vaccines
  • 9.4 Individualized mRNA Cancer Vaccines
  • 9.5 Replicon RNA Infectious Disease Vaccines
  • 9.6 Prophylactic mRNA Infectious Disease Vaccines
  • 9.7 mRNA Protein Therapeutics for Ornithine TransCarbomylase Deficiency
  • 9.8 mRNA Protein Therapeutics for Cancer and Cardiovascular Diseases
  • 9.9 mRNA Protein Therapeutics for Cystic Fibrosis
  • 9.10 mRNA Protein Therapeutics for Other Genetic Diseases
  • 9.11 Therapeutic mRNA-based Gene Editing
  • 9.12 mRNA Antibody Therapeutics

10. Leading Companies in the mRNA Vaccines and Therapeutics Market

  • 10.1 Moderna Therapeutics
    • 10.1.1 Product Portfolio
    • 10.1.2 Financial Overview
    • 10.1.3 Strategic Developments
  • 10.2 Sangamo Therapeutics
    • 10.2.1 Product Portfolio
    • 10.2.2 Financial Overview
    • 10.2.3 Strategic Developments
  • 10.3 Argos Therapeutics
    • 10.3.1 Product Portfolio
    • 10.3.2 Financial Overview
    • 10.3.3 Strategic Developments
  • 10.4 CureVac
    • 10.4.1 Product Portfolio
    • 10.4.2 Financial Overview
    • 10.4.3 Strategic Developments
  • 10.5 Translate Bio
    • 10.5.1 Product Portfolio
    • 10.5.2 Financial Overview
    • 10.5.3 Strategic Developments
  • 10.6 BioNTech
    • 10.6.1 Product Portfolio
    • 10.6.2 Financial Overview
    • 10.6.3 Strategic Developments
  • 10.7 In-Cell-Art
    • 10.7.1 Product Portfolio
    • 10.7.2 Financial Overview
    • 10.7.3 Strategic Developments
  • 10.8 eTheRNA Immunotherapies
    • 10.8.1 Product Portfolio
    • 10.8.2 Financial Overview
    • 10.8.3 Strategic Developments
  • 10.9 ethris GmbH
    • 10.9.1 Product Portfolio
    • 10.9.2 Financial Overview
    • 10.9.3 Strategic Developments
  • 10.10 Tiba Biotech
    • 10.10.1 Product Portfolio
    • 10.10.2 Financial Overview
    • 10.10.3 Strategic Developments

11. Conclusion

  • 11.1 The World mRNA Vaccines and Therapeutics Market in 2018-2029
  • 11.2 Current Leading mRNA Vaccines and Therapeutics Segments
  • 11.3 Leading mRNA Vaccines and Therapeutics Companies
  • 11.4 Leading Regional Markets

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain report evaluation form

List of Tables

  • Table 4.1 Global mRNA Vaccines and Therapeutics Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 6.1 Global mRNA Vaccines and Therapeutics Market Forecast by Type: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 6.2 Global Standardized Therapeutic Cancer mRNA Vaccines Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 6.3 Global Individualized Therapeutic Cancer mRNA Vaccines Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 6.4 Global Therapeutic Infectious Disease mRNA Vaccines Market Forecast: Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 6.5 Global mRNA Therapeutic for Other Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 7.1 Global mRNA Vaccines and Therapeutics Market Forecast by Mechanism of Action: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 7.2 Global Bioengineered Vaccine Market Forecast: Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 7.3 Global Gene Therapy (Gene Silencing/Suppression) Market Forecast: Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 7.4 Global Gene Transcription (Protein Generation) Market Forecast: Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 7.5 Global Cell Therapy Market Forecast: Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 7.6 Global Monoclonal Antibody Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 7.7 Global Other Mechanism of Actions Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029
  • Table 8.1 World mRNA Vaccines and Therapeutics Market by Region: Revenue ($bn) and Market Share (%) 2018 and 2029
  • Table 8.2 Global mRNA Vaccines and Therapeutics Market Forecast by Region: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 8.3 North America mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 8.4 North America mRNA Vaccines and Therapeutics Market Forecast by Country: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 8.5 US mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
  • Table 8.6 Canada mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 8.7 Europe mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 8.8 Europe mRNA Vaccines and Therapeutics Market Forecast by Country: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 8.9 Germany mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 8.10 UK mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 8.11 French mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 8.12 Italian mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 8.13 Spanish mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
  • Table 8.14 Asia-Pacific mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 8.15 Asia-Pacific mRNA Vaccines and Therapeutics Market Forecast by Country: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 8.16 Japanese mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 8.17 Chinese mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 8.18 Indian mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
  • Table 8.19 RoW mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 8.20 RoW mRNA Vaccines and Therapeutics Market Forecast by Country: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 8.21 Brazilian mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 8.22 Mexico mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 8.23 Russia mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 8.24 South Africa mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 9.1 Promising mRNA Vaccines and Therapies Pipeline Molecules Analysis, 2018
  • Table 9.2 Standardized mRNA Cancer Vaccines Pipeline Molecules Analysis, 2018
  • Table 9.3 Standardized mRNA Cancer Vaccines Pipeline Molecules Analysis, 2018
  • Table 9.4 Individualized mRNA Cancer Vaccines Pipeline Molecules Analysis, 2018
  • Table 9.5 Prophylactic mRNA Infectious Disease Vaccines Pipeline Molecules Analysis, 2018
  • Table 9.6 mRNA Protein Therapeutics for Ornithine TransCarbomylase Deficiency Pipeline Molecules Analysis, 2018
  • Table 9.7 mRNA Protein Therapeutics for Cancer and Cardiovascular Diseases Pipeline Molecules Analysis, 2018
  • Table 9.8 mRNA Protein Therapeutics for Cystic Fibrosis Pipeline Molecules Analysis, 2018
  • Table 9.9 mRNA Protein Therapeutics for Cystic Fibrosis Pipeline Molecules Analysis, 2018
  • Table 9.10 mRNA Protein Therapeutics for Cystic Fibrosis Pipeline Molecules Analysis, 2018
  • Table 9.11 mRNA Antibody Therapeutics Pipeline Molecules Analysis, 2018
  • Table 10.1 Overview: Moderna Therapeutics
  • Table 10.2 Moderna Therapeutics: Product Portfolio
  • Table 10.3 Recent Developments: Moderna Therapeutics
  • Table 10.4 Overview: Sangamo Therapeutics
  • Table 10.5 Sangamo Therapeutics: Product Portfolio
  • Table 10.6 Recent Developments: Sangamo Therapeutics, Inc.
  • Table 10.7 Overview: Argos Therapeutics
  • Table 10.8 Argos Therapeutics: Product Portfolio
  • Table 10.9 Recent Developments: Argos Therapeutics, Inc.
  • Table 10.10 Overview: CureVac
  • Table 10.11 CureVac: Product Portfolio
  • Table 10.12 Recent Developments: CureVac AG
  • Table 10.13 Overview: Translate Bio
  • Table 10.14 Translate Bio: Product Portfolio
  • Table 10.15 Recent Developments: Translate Bio
  • Table 10.16 Overview: BioNTech
  • Table 10.17 BioNTech: Product Portfolio
  • Table 10.18 Recent Developments: BioNTech
  • Table 10.19 Overview: In-Cell-Art
  • Table 10.20 In-Cell-Art: Product Portfolio
  • Table 10.21 Recent Developments: Translate Bio
  • Table 10.22 Overview: eTheRNA Immunotherapies
  • Table 10.23 eTheRNA Immunotherapies: Product Portfolio
  • Table 10.24 Recent Developments: Translate Bio
  • Table 10.25 Overview: Ethris GmbH
  • Table 10.26 Ethris GmbH: Product Portfolio
  • Table 10.27 Recent Developments: ethris GmbH
  • Table 10.28 Overview: Tiba Biotech
  • Table 10.29 Tiba Biotech: Product Portfolio

List of Figures

  • Figure 4.1 Global mRNA Vaccines and Therapeutics Market Forecast Revenue ($bn), AGR (%) 2019-2029
  • Figure 4.2 Global mRNA Vaccines and Therapeutics Market Forecast Share (%) by Region 2019-2029
  • Figure 5.1 mRNA Vaccines and Therapeutics Market: Drivers and Restraints 2019-2029
  • Figure 6.1 Global mRNA Vaccines and Therapeutics Market Forecast by Type: Revenue ($bn), 2019-2029
  • Figure 6.2 Global mRNA Vaccines and Therapeutics Market Forecast by Type: Market Share (%), 2019-2029
  • Figure 6.3 Global mRNA Vaccines and Therapeutics Market Forecast by Type: Market Shares (%), 2018
  • Figure 6.4 Global mRNA Vaccines and Therapeutics Market Forecast by Type: Market Shares (%), 2024
  • Figure 6.5 Global mRNA Vaccines and Therapeutics Market Forecast by Type: Market Shares (%), 2029
  • Figure 6.6 Global Standardized Therapeutic Cancer mRNA Vaccines Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 6.7 Global Individualized Therapeutic Cancer mRNA Vaccines Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 6.8 Global Therapeutic Infectious Disease mRNA Vaccines Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 6.9 Global mRNA Therapeutic for Other Diseases Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 7.1 Global mRNA Vaccines and Therapeutics Market Forecast by Mechanism of Action: Revenue ($bn) 2019-2029
  • Figure 7.2 Global mRNA Vaccines and Therapeutics Market Forecast by Mechanism of Action: Market Share (%) 2019-2029
  • Figure 7.3 Global mRNA Vaccines and Therapeutics Market Forecast by Mechanism of Action: Market Shares (%), 2018
  • Figure 7.4 Global mRNA Vaccines and Therapeutics Market Forecast by Mechanism of Action: Market Shares (%), 2024
  • Figure 7.5 Global mRNA Vaccines and Therapeutics Market Forecast by Mechanism of Action: Market Shares (%), 2029
  • Figure 7.6 Global Bioengineered Vaccine Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 7.7 Global Gene Therapy (Gene Silencing/Suppression) Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 7.8 Global Gene Transcription (Protein Generation) Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 7.9 Global Cell Therapy Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 7.10 Global Monoclonal Antibody Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 7.11 Global Other Mechanism of Actions Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 8.1 Global mRNA Vaccines and Therapeutics Market by Region: Revenues (%), 2018
  • Figure 8.2 Global mRNA Vaccines and Therapeutics Market by Region: Revenues (%), 2024
  • Figure 8.3 Global mRNA Vaccines and Therapeutics Market by Region: Revenues (%), 2029
  • Figure 8.4 North America mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 8.5 North America mRNA Vaccines and Therapeutics Market Forecast by Region: Share (%) 2019-2029
  • Figure 8.6 US mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 8.7 Canada mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 8.8 Europe mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 8.9 Europe mRNA Vaccines and Therapeutics Market by Country: Share (%), 2019-2029
  • Figure 8.10 Germany mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 8.11 UK mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 8.12 French mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 8.13 Italian mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 8.14 Spanish mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 8.15 Asia-Pacific mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 8.16 Asia-Pacific mRNA Vaccines and Therapeutics Market by Country: Share (%), 2019-2029
  • Figure 8.17 Japanese mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 8.18 Chinese mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 8.19 Indian mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 8.20 RoW mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 8.21 RoW mRNA Vaccines and Therapeutics Market by Country: Share (%), 2018-2029
  • Figure 8.22 Brazilian mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 8.23 Mexico mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 8.24 Russia mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 8.25 South Africa mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 10.1 Moderna Therapeutics: Financial Overview, 2016-2018
  • Figure 10.2 Sangamo Therapeutics: Financial Overview, 2016-2018
  • Figure 10.3 Argos Therapeutics: Financial Overview, 2016-2018
  • Figure 11.1 Global mRNA Vaccines and Therapeutics Market Forecast: Revenue ($bn), AGR (%) 2019-2029
  • Figure 11.2 Global mRNA Vaccines and Therapeutics Market Forecast by Country: Share (%) 2019-2029

COMPANIES LISTED:

  • Adaptive Biotechnologies Corporation
  • Arcturus Therapeutics Ltd.
  • Argos Therapeutics, Inc.
  • AstraZeneca
  • Bayer
  • BioNet-Asia
  • BioNTech AG
  • BioNTech Diagnostics GmbH
  • Bioverativ Inc.
  • Brammer Bio
  • Caperna LLC
  • CELLSCRIPT, LLC
  • CureVac AG
  • Dow AgroSciences LLC
  • Effimune
  • Eli Lilly and Company
  • Elpidera LLC
  • eTheRNA immunotherapies NV
  • ethris GmbH
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Genevant Sciences
  • In-Cell-Art
  • Institut Pasteur
  • Kite Pharma, Inc.
  • MAB Discovery GmbH
  • Merck & Co.
  • Metropolis Healthcare Ltd.
  • Moderna Therapeutics
  • Mymetics BV
  • Mymetics Corporation
  • Okinawa Health Biotechnology Research and Development Center
  • Open Monoclonal Technology, Inc.
  • PCI Biotech
  • Personalis, Inc.
  • Pfizer Inc.
  • Pharmaceutical Product Development, LLC (PPD)
  • Sangamo Therapeutics, Inc.
  • Sanofi Pasteur S.A.
  • Shire International GmbH
  • Shuwen Biotech Co. Ltd.
  • Sigma-Aldrich Corporation
  • Tiba Biotech LLC
  • Translate Bio
  • Translate Bio, Inc.
  • TxCell, SA
  • Valeant Pharmaceuticals International Inc.
  • Valera LLC
  • Vertex Pharmaceuticals
  • Virbac

List of Organizations Mentioned in the Report:

  • American Cancer Society
  • American Diabetes Organization
  • Bill & Melinda Gates Foundation
  • Biomedical Advanced Research and Development Authority (BARDA)
  • Cancer Research UK
  • Defense Advanced Research Projects Agency
  • Friedrich-Loeffler-Institute
  • Institute of Immunology of the Centre de Recherche Public-Santé (CRP)
  • Karolinska Institutet
  • Karolinska University Hospital (KUH)
  • The Coalition for Epidemic Preparedness Innovations (CEPI)
  • U.S. Food and Drug Administration (FDA)
  • University of Pennsylvania (Penn)
  • World Health Organization (WHO)
Back to Top